Navigation Links
OrbusNeich's Genous(TM) Bio-engineered R stent(TM) Demonstrates Excellent Safety and Clinical Outcomes in High-Risk Elderly Patients
Date:4/29/2010

SEOUL, South Korea, April 29 /PRNewswire/ -- OrbusNeich today announced that a subset analysis of patients over 70 years of age in the final 12-month clinical results of the global e-HEALING Registry confirmed that the company's Genous Bio-engineered R stent is safe and demonstrates excellent clinical outcomes in this high-risk patient group.

The data were presented by Dr. Andres Iniguez, M.D., of the Hospital Universitario de Vigo in Vigo, Spain, at the Angioplasty Summit Transcatheter Cardiovascular Therapeutics Conference Asia Pacific (TCTAP) 2010 in Seoul, South Korea.  

The subset analysis evaluated 1,567 patients with a mean age of 75 years old from the e-HEALING clinical study and found a composite hierarchical major adverse cardiac event (MACE) rate of 9.9 percent with no Q-wave myocardial infarction (MI) at 12 months. The target lesion revascularization (TLR) rate was 6.7 percent, and the rate of target vessel failure (TVF) was 10.4 percent at 12 months.  Per Academic Research Consortium (ARC) definition, the definite and probable subacute thrombosis (SAT) rate at 12 months was 0.9 percent, and the rate of late stent thrombosis (LST) was 0.3 percent.

Of the 1,063 male (67.8%) and 504 female (32.2%) patients, 39 percent had a prior acute myocardial infarction. Of the 2,169 lesions treated in the patient subset, 54.5 percent were type B2 or C. The study protocol recommends that patients receive one month of dual antiplatelet therapy post index procedure.

"Elderly patients represent an important segment of individuals undergoing PCI procedures," said Dr. Iniguez, the presenter of the study. "We are especially pleased to see excel
'/>"/>

SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Data Presented at ACC/i2 Summit Demonstrate Impressive Long Term Clinical Outcomes in Real World Patients Treated with OrbusNeichs Genous(TM) Bio-engineered R stent(TM)
2. OrbusNeich Announces First Patient Enrolled in Randomized Clinical Trial of Genous(TM) Bio-engineered R stent(TM) in China
3. Clinical Data Presented at Asia PCR/Sing LIVE Demonstrate Benefits of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) in Challenging Patient Subsets
4. Data From Multiple Clinical Trials of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2009
5. Long Term Data Presented at EuroPCR 2009 from Randomized Study Attest to Durability of Results of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) Compared to Drug-Eluting Stents
6. Interim Analysis of 12-Month Data from e-HEALING Registry Shows Good Safety and Efficacy in Real-World Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM)
7. Data From Multiple Clinical Trials of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2008
8. Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents
9. Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents
10. Data from Randomized Pilot Study, Real-World Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented in Symposium at EuroPCR 2008
11. Clinical Impact of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) is Subject of Symposium at 16th Annual Scientific Congress of Hong Kong College of Cardiology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... , October 17, 2014 ... ) has announced the addition of the  ... to their offering.       (Logo: ... disease in China ... changes in consumption concept, dietary habit, way ...
(Date:10/17/2014)... DUBLIN , October 17, 2014 ... Research and Markets ( http://www.researchandmarkets.com/research/rxznjk/micro_market ) has ... Market Monitor : North American Automated ... their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,The ... forecast, 2008-2018 analyzes the market of ...
(Date:10/17/2014)... 17, 2014 The following is being ... The Green Park Collaborative (GPC) will ... private payers, medical device and pharmaceutical companies, as ... January 12, 2015 at its first ever workshop ... loss treatments.  Participants will discuss study designs to ...
Breaking Medicine Technology:China Interventional Cardiovascular Device Industry Report 2014-2017 2China Interventional Cardiovascular Device Industry Report 2014-2017 3Micro Market Monitor : North American Automated External Defibrillators (AED) Market 2Green Park Collaborative to Discuss Comparative Effectiveness and Value of Weight Loss Treatments 2
... - Introgen Therapeutics, Inc.,(NASDAQ:INGN) reported promising Phase 1/2 ... mda-7/IL-24 tumor,suppressor agent, in patients with advanced solid ... today at the,annual meeting of the American Society ... INGN 241 induced killing in all treated,tumors, including ...
... Company Planning to Initiate Phase 2 Trials ... in Q307 -, SOUTH SAN FRANCISCO, Calif., ... , a,biopharmaceutical company focused on oncology, today ... of two Phase 1,dose-escalating trials of picoplatin, ...
Cached Medicine Technology:Introgen Reports Promising Phase 1/2 Clinical Results With INGN 241,in Patients With Advanced Solid Tumors 2Introgen Reports Promising Phase 1/2 Clinical Results With INGN 241,in Patients With Advanced Solid Tumors 3Poniard Pharmaceuticals Announces Promising Data From Interim,Safety Analysis of Phase 1 Combination Trials of Picoplatin in,Colorectal and Prostate Cancers 2Poniard Pharmaceuticals Announces Promising Data From Interim,Safety Analysis of Phase 1 Combination Trials of Picoplatin in,Colorectal and Prostate Cancers 3Poniard Pharmaceuticals Announces Promising Data From Interim,Safety Analysis of Phase 1 Combination Trials of Picoplatin in,Colorectal and Prostate Cancers 4Poniard Pharmaceuticals Announces Promising Data From Interim,Safety Analysis of Phase 1 Combination Trials of Picoplatin in,Colorectal and Prostate Cancers 5Poniard Pharmaceuticals Announces Promising Data From Interim,Safety Analysis of Phase 1 Combination Trials of Picoplatin in,Colorectal and Prostate Cancers 6
(Date:10/20/2014)... 20, 2014 Principle Business Enterprises, a ... in manufacturing top-of-the-line absorbent products. The company has ... most popular brand, Tranquility® Premium Protection absorbent products. ... website, gave its packaging a new look, and is ... message to the public. , The new website, developed ...
(Date:10/20/2014)... Succeed is proud to announce that they ranked in the ... Every Body Walk! campaign by Kaiser Permanente. Every ... to be more active outside of the workplace. This ... end of September, was a friendly competition between organizations across ... companies gave their staff pedometers and each day, for the ...
(Date:10/20/2014)... October 20, 2014 Unveiled at the Sept. ... Direction Scorecard conservatively estimates member hospital ROI on membership dues ... dues, The Center provides $12.50 in value to member hospitals. ... Value – Member Dues)/Member Dues. , “This is the ... number and we think the methodology is really sound,” said ...
(Date:10/20/2014)... Spring, Maryland, USA (PRWEB) October 20, 2014 ... or to track interventions? Here comes a wonderful app ... mobile app development company helped its client ... Intervention more efficiently. The app is designed for iOS ... and iPod touch. This app is optimized for iPhone ...
(Date:10/19/2014)... NATIONS, New York (PRWEB) October 19, 2014 ... United Nations Population Fund, welcomes news of a ceasefire ... of the more than 200 girls who were kidnapped ... "These girls have languished in captivity long enough, and ... families, schools and communities," stated Dr. Osotimehin. , "We ...
Breaking Medicine News(10 mins):Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3
... Kan., Jan. 28 Fort Dodge Animal Health,a ... the American Association of Equine,Practitioners (AAEP) recently announced ... raise awareness regarding the health of horses.,Americashealthyhorse.com provides ... The America,s Healthy Horse Web site will aide ...
... -- The Cystic Fibrosis Foundation reported today that key ... including lung function and nutritional status -- are rising ... fact, the outlook for people with CF continues to ... accelerating due to quality improvement programs spearheaded by the ...
... To support,Pennsylvanians who made a New Year,s resolution ... announced that Governor Edward G.,Rendell has proclaimed Jan. 28 ... "Determined to Quit Week is all about motivating Pennsylvanians ... Secretary of,Health Dr. Calvin B. Johnson. "For anyone who ...
... to Expand Profile with Area Representatives, TAMPA, ... leading study program, announces a new program to ... Area,Representatives will travel to massage schools nationwide to ... so comprehensive that,Massage Prep guarantees passage of the ...
... ... Presenting at the UBS Global Healthcare Services Conference on Tuesday, ... February 12, 2008, CINCINNATI, Jan. ... the,LasikPlus brand, announced today upcoming investment community events., Fourth Quarter & Full-Year 2007 ...
... Russian women who smoke has more than doubled since the ... In 1992, seven per cent of women smoked, compared to ... the number of men who smoke has risen from 57 ... the study, published in the journal Tobacco Control, blame the ...
Cached Medicine News:Health News:Fort Dodge Animal Health and the American Association of Equine Practitioners Launch Educational Web Site 2Health News:Cystic Fibrosis Foundation reports upward trend for key health outcomes 2Health News:Massage Prep(TM) Announces Outreach Program 2Health News:LCA-Vision Announces Upcoming Investment Community Events 2Health News:Number of Russian women smokers has doubled since Soviet collapse 2
Leica M500 MS3 robotic stand for neuro, spine surgery and ENT. Motorized XY-movement for precise positioning of the optical axis in eight directions, inclination and tilt....
Advanced operating microscope with high-resolution apochromatic optics. Senso-servo drive to keep the microscope in perfect balance even if parts are moved or mounted elsewhere....
... provides surgeons with brighter, crisper, magnified views ... for many minimally invasive spine procedures. It ... point of contact. The first graphical touchscreen ... allows intuitive user guidance similar to that ...
DUALSWITCH-SHUNTSYSTEM for L-P-Derivation...
Medicine Products: